Sec61 inhibitors

#Enodia Therapeutics #Pfizer #Protein degradation #Sec61 inhibitors #Small molecules

Enodia Therapeutics and Pfizer to develop Sec61-targeting small molecules 

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors.   The collaboration aims to accelerate the discovery and advancement of novel small-molecule… Read More

#News